Skip to content

Released Aug 8, 2024, after the close

10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-036231

Q2 2024 · 10-Q
Revenue$56.21M−30.2% vs Q2 2023+48.1% vs Q1 2024
Net Income-$217.18MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$4.23N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$222,945,000N/M
Operating Cash Flowderived-$84,390,000N/M
Free Cash Flowderived-$111,422,000N/M
Margins · derived
Operating margin-396.7%−168.1 pt vs Q2 2023
Net margin-386.4%−171.3 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$56.21M$80.57M$144.62M$43.64M
Net Income-$217.18M-$173.32M-$668.83M-$53.94M
EPS Diluted-$4.23-$0.09-$0.41-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR